COVID-19

Regeneron Provides Update on Biologics License Application for Linvoseltamab

TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and…

4 months ago

Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics…

4 months ago

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023

CHICAGO, IL / ACCESSWIRE / August 20, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

4 months ago

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

CHICAGO, IL / ACCESSWIRE / August 20, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

4 months ago

Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference

Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI…

4 months ago

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential…

4 months ago

Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update

Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand…

4 months ago

UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions

SHENZHEN, China, Aug. 19, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce a…

4 months ago

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company…

4 months ago